Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income/(Loss)
Beginning balance at Dec. 31, 2020	$ 23,382	$ 3	$ 216,305	$ (192,935)	$ 9
Beginning balance, shares at Dec. 31, 2020		27,074,791
Net loss	(82,553)			(82,553)
Issuance of common stock upon exercise of stock option grants	8,749		8,749
Issuance of common stock upon exercise of stock option grants, shares		978,495
Issuance of common stock related to exercise of warrants	40,172		40,172
Issuance of common stock related to exercise of warrants, shares		1,039,960
Issuance of common stock in connection with acquisition of Healing Solutions assets	39,454		39,454
Issuance of common stock in connection with acquisition of Healing Solutions assets, shares		1,387,759
Issuance of restricted stock awards	3,427		3,427
Issuance of restricted stock awards, shares		109,791
Stock-based compensation expense	5,804		5,804
Other comprehensive income (loss)	30				30
Ending balance at Mar. 31, 2021	38,465	$ 3	313,911	(275,488)	39
Ending balance, shares at Mar. 31, 2021		30,590,796
Beginning balance at Dec. 31, 2021	224,228	$ 5	653,650	(428,959)	(468)
Beginning balance, shares at Dec. 31, 2021		55,090,237
Net loss	(42,776)			(42,776)
Issuance of shares of restricted common stock		155,456
Forfeiture of shares of restricted common stock		(193,594)
Issuance of common stock for settlement of seller note	767		767
Issuance of common stock for settlement of seller note, shares		292,887
Issuance of common stock, net of issuance costs	27,007	$ 1	27,006
Issuance of common stock, net of issuance costs, shares		7,003,332
Issuance of warrants in connection with offering	18,982		18,982
Loss on initial issuance of equity	5,835		5,835
Stock-based compensation expense	1,444		1,444
Other comprehensive income (loss)	(171)				(171)
Ending balance at Mar. 31, 2022	197,352	$ 6	669,720	$ (471,735)	$ (639)
Ending balance, shares at Mar. 31, 2022		62,348,318
Issuance of warrants in connection with offering	$ (18,982)		$ (18,982)